scholarly journals Performance of a Novel Blood-Based Early Colorectal Cancer Screening Assay in Remaining Serum after the Blood Biochemical Test

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Ying Chen ◽  
Zhenzhen Wang ◽  
Guodong Zhao ◽  
Chuang Sun ◽  
Yong Ma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Early Colorectal Cancer ◽  
Effective Strategy ◽  
Serum Samples ◽  
Screening Assay ◽  
Crc Screening ◽  
Blood Biochemical ◽  
Multiple Biomarkers ◽  
Cancer Tissues

Background. Combination of multiple biomarkers was an effective strategy to improve sensitivity in cancer diagnosis and screening. However, the performance of the combination of methylated SEPT9 and SDC2 for detection of colorectal cancer (CRC) has yet to be reported. Methods. A new qPCR-based assay combining the detection of methylated SEPT9 and SDC2 was used. Methylation statuses of SEPT9 and SDC2 were examined in 19 sets of cancer tissues and paired adjacent tissues and further evaluated with 225 serum samples, including 111 CRC patients and 114 no evidence of disease individuals. Results. SEPT9 and SDC2 methylation levels were higher in 94.7% and 100.0% of cancer tissues than in their paired adjacent tissues. The sensitivities for detecting CRC by SEPT9 methylation alone and SDC2 methylation alone were 73.0% (95% CI: 63.6–80.8%) and 71.2% (95% CI: 61.8–79.2%), respectively, with the same specificity of 95.6% (95% CI: 89.6–98.4%). However, when SEPT9 methylation was combined with SDC2 methylation to detect CRC, the sensitivity was improved to 86.5% (95% CI: 78.4–92.0%) with a specificity of 92.1% (95% CI: 85.1–96.1%). Conclusion. The combination of methylated SEPT9 and SDC2 detection in serum has the potential to be a noninvasive strategy for CRC screening.

Recent advances in fecal gene detection for colorectal cancer diagnosis

2021 ◽  
Vol 15 (14) ◽  
pp. 1299-1308
Author(s):  
Siyu He ◽  
Chenglin Zhou ◽  
Hailin Peng ◽  
Mei Lin
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Gradual Increase ◽  
Dynamic Monitoring ◽  
Gene Detection ◽  
Crc Screening ◽  
Prognostic Assessment ◽  
Advanced Stages ◽  
Continuous Dynamic Monitoring ◽  
Continuous Dynamic

There has been a gradual increase in the incidence of colorectal cancer (CRC) in recent years. Most patients lack obvious early symptoms, but are commonly in mid and advanced stages when the symptoms become evident, with rather high mortalities. Early diagnosis, treatment and recurrence monitoring are crucial to improving the recovery rate of CRC. Studies have shown that tumor-related genes can be detected in the feces of CRC patients. Owing to non-invasiveness, convenient sampling and continuous dynamic monitoring, fecal gene detection may be applicable to CRC screening, diagnosis, prognostic assessment and recurrence monitoring. Herein, we review the research advances in fecal gene detection for CRC diagnosis.

A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2

2020 ◽  
Vol 503 ◽  
pp. 84-89 ◽  
Author(s):  
Guodong Zhao ◽  
Yong Ma ◽  
Hui Li ◽  
Shiming Li ◽  
Yun Zhu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Colorectal Cancer Screening ◽  
Early Colorectal Cancer ◽  
Screening Assay

Development of a new mathematical tool for early colorectal cancer diagnosis and its possible use in mass screening

2019 ◽  
Vol 22 (6) ◽  
pp. 811-835
Author(s):  
Antonio Battista ◽  
Rosa Alessia Battista ◽  
Federica Battista ◽  
Luigi Cinquanta ◽  
Gerardo Iovane ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mass Screening ◽  
Cancer Diagnosis ◽  
Early Colorectal Cancer ◽  
Mathematical Tool

Early colorectal cancer: diagnosis, treatment and survivorship care

2019 ◽  
Vol 136 ◽  
pp. 20-30 ◽  
Author(s):  
Gabriella Buccafusca ◽  
Ilaria Proserpio ◽  
Antonino Carmelo Tralongo ◽  
Sebastiano Rametta Giuliano ◽  
Paolo Tralongo
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Early Colorectal Cancer ◽  
Survivorship Care

scholarly journals Improved Stool DNA Integrity Method for Early Colorectal Cancer Diagnosis

2014 ◽  
Vol 23 (11) ◽  
pp. 2553-2560 ◽  
Author(s):  
Claudia Rengucci ◽  
Giulia De Maio ◽  
Maura Menghi ◽  
Emanuela Scarpi ◽  
Simona Guglielmo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Early Colorectal Cancer ◽  
Dna Integrity ◽  
Stool Dna

scholarly journals Multiple Biomarker-Combined Screening for Colorectal Cancer Based on Bisulfate Conversion-Free Detection of Fecal DNA Methylation

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Chong Liu ◽  
Lei Xu ◽  
Wei Li ◽  
Min Jie ◽  
Wei Xue ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Lines ◽  
Enzyme Digestion ◽  
Detection Sensitivity ◽  
Clinical Samples ◽  
Crc Screening ◽  
Methylation Assay ◽  
Multiple Biomarkers ◽  
Stool Samples ◽  
Advanced Adenomas

To evaluate the applicability of bisulfate conversion-free methylation assay based on enzyme digestion in fecal screening for colorectal cancer (CRC). Stool samples were collected from a total of 1142 participants with intestinal abnormalities, including 180 positive cases, 60 advanced adenomas, and 902 negative cases. DNA from reference cell lines and clinical samples was extracted and digested with an enzyme to detect the methylation of CRC markers SEPT9, SDC2, NDRG4, SFRP2, and BMP3 genes. Statistical analysis was then used to determine the ability of the markers, both individually and in combination, to detect CRC and adenoma. Our results showed that the enzyme digestion method could suitably detect DNA marker methylation in as low as 1% of the cell lines. BMP3 had a considerably low detection rate in all clinical samples, with only 6 positive cases detected out of 180 cancer samples. Our findings showed that the combination of SEPT9, SDC2, and SFRP2 had an area under the receiver operation curve of 0.937, sensitivity of 94.11%, and specificity of 89.21% for detecting CRC. Moreover, the detection sensitivity of adenoma can also reach 38.33%. After innovatively utilizing bisulfate conversion-free methylation assay for CRC screening, this study verified the potential clinical applicability of combining multiple biomarkers for CRC screening in a large number of samples.

Rurality and Other Determinants of Early Colorectal Cancer Diagnosis in Nebraska: A 6-Year Cancer Registry Study, 1998-2003

2009 ◽  
Vol 25 (4) ◽  
pp. 358-365 ◽  
Author(s):  
Jayashri Sankaranarayanan ◽  
Shinobu Watanabe-Galloway ◽  
Junfeng Sun ◽  
Fang Qiu ◽  
Eugene Boilesen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Registry ◽  
Cancer Diagnosis ◽  
Early Colorectal Cancer ◽  
Registry Study

scholarly journals RNAM EXPRESSION AND DNA METHYLATION OF DKK2 GENE IN COLORECTAL CÂNCER

2021 ◽  
Vol 58 (1) ◽  
pp. 55-60
Author(s):  
Ronaldo Eliezer MAMELLI ◽  
Aledson Vitor FELIPE ◽  
Tiago Donizetti SILVA ◽  
Vanessa HINZ ◽  
Nora Manoukian FORONES
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Overall Survival ◽  
Cancer Diagnosis ◽  
Promoter Methylation ◽  
Cpg Islands ◽  
Polymerase Chain Reaction Analysis ◽  
Diagnosis And Prognosis ◽  
Melting Analysis ◽  
Cancer Tissues

ABSTRACT BACKGROUND: Colorectal cancer is the third most common neoplasm in the world. Methylation of tumor related genes in CpG islands can cause gene silencing and been involved in the development of cancer. The potential role of DKK2 as a biomarker for early diagnosis of colorectal cancer remains unclear. OBJECTIVE: The aim of the study was to evaluate the profile of methylation and RNAm expression of DKK2 as potential predictors of colorectal cancer diagnosis and prognosis. METHODS: Expression of mRNAs encoding DKK2 in 35 colorectal cancer tissues was quantified using real-time polymerase chain reaction analysis. The DNA methylation was studied by high resolution melting analysis. The general characteristics of the patients were collected. DKK2 methylation and expression were compared to clinical, pathological aspects and overall survival. RESULTS: Among the 35 patients studied, 18 were male, 10 were on right colon and 25 on left colon. Among the 20 patients with high hypermethylation, 15 of them had mRNA low expression of DKK2. There was no significant association between DKK2 promoter methylation and mRNA DKK2 expression and clinical or pathological features. DKK2 promoter methylation (P=0.154) and DKK2 RNA expression (P=0.345) did not show significant correlation with overall survival. CONCLUSION: DKK2 promoter methylation and DKK2 RNA status appear to be biomarkers of cancer diagnosis but not predictors of prognosis.

scholarly journals KCNQ5 and C9orf50 Methylation in Stool DNA for Early Detection of Colorectal Cancer

2021 ◽  
Vol 10 ◽  
Author(s):  
Yaping Cao ◽  
Guodong Zhao ◽  
Mufa Yuan ◽  
Xiaoyu Liu ◽  
Yong Ma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Performance ◽  
Advanced Adenoma ◽  
Early Colorectal Cancer ◽  
Crc Screening ◽  
Alternative Approach ◽  
Significant Difference ◽  
Stool Dna ◽  
Aberrant Dna Methylation ◽  
Screening And Prevention

BackgroundAberrant DNA methylation has emerged as a class of promising biomarkers for early colorectal cancer (CRC) detection, but the performance of methylated C9orf50 and methylated KCNQ5 in stool DNA has never been evaluated.MethodsMethylation specific quantitative PCR (qPCR) assays for methylated C9orf50 and methylated KCNQ5 were developed. The methylation levels of C9orf50 and KCNQ5 in 198 CRC patients, 20 advanced adenoma (AA) patients, 101 small polyp (SP) patients, and 141 no evidence of disease (NED) subjects were analyzed.ResultsThe methylation levels of both KCNQ5 and C9orf50 genes were significantly higher in CRC and AA groups than those in SP and NED groups, but showed no significant difference among different stages of CRC. The sensitivities of methylated KCNQ5 and methylated C9orf50 for CRC detection were 77.3% (95% CI: 70.7–82.8%) and 85.9% (95% CI: 80.0–90.2%) with specificities of 91.5% (95% CI: 85.3–95.3%) and 95.0% (95% CI: 89.7–97.8%), respectively. When C9orf50 and methylated KCNQ5 were combined, the clinical performance for CRC detection was similar to that of methylated C9orf50 alone.ConclusionsStool DNA based methylated C9orf50 test has the potential to become an alternative approach for CRC screening and prevention.

Sign in / Sign up

Export Citation Format

Share Document